
Cyclacel Pharmaceuticals (CYCC)
Order type
Buy in
Order amount
Est. shares
0 shares
Buy Cyclacel Pharmaceuticals (CYCC) Stock
Start investing in Cyclacel Pharmaceuticals (CYCC)
About Cyclacel Pharmaceuticals (CYCC)
Market cap | $9.18M |
Today's volume | 1.68M |
Revenue (TTM) | $14K |
Avg. daily volume | 956.72K |
EBITDA (TTM) | -$13.47M |
Open | $0.39 |
Price / earnings ratio | -0.01x |
Today's range | $0.31 - $0.39 |
Debt / equity | 0.29x |
52 week range | $0.25 - $39.84 |
5 year debt / equity | 1.97x |
Beta (LTM) | 0.45x |
Interest coverage | — |
Dividend & yield | $0.00 (0.00%) |
Current ratio | 5.6x |
Ex-dividend date | — |
Next earnings | Aug 13, 2025 |
Dividend payable date | — |
Cyclacel Pharmaceuticals Stock Rating
Cyclacel Pharmaceuticals Stock News
View all



Frequently Asked Questions (FAQ)
How to buy CYCC stock on Public
- 1
Sign up for a brokerage account on Public
It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.
- 2
Add funds to your Public account
There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.
- 3
Choose how much you'd like to invest in CYCC stock
Navigate to the Explore page. Then, type CYCC into the search bar. When you see CYCC stock appear in the results, tap it to open up the purchase screen.
- 4
Manage your investments in one place
You can find your newly purchased CYCC stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.
Cyclacel Pharmaceuticals Stock Earnings
The value each CYCC share was expected to gain vs. the value that each CYCC share actually gained.
Cyclacel Pharmaceuticals (CYCC) reported Q4 2024 earnings per share (EPS) of -$0.33, missing estimates of -$0.29 by 13.79%. In the same quarter last year, Cyclacel Pharmaceuticals's earnings per share (EPS) was -$6.23. Cyclacel Pharmaceuticals is expected to release next earnings on 08/13/2025, with an earnings per share (EPS) estimate of -$0.29.